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Glaucoma is the leading cause of irreversible blindness. Current estimates 
point to 65 million people over 40 years aff ected by glaucoma. Projections 
are 76 and 111 million for 2020 and 2040, respectively1. We will have a 74% 
increase in prevalence over the next 27 years, of this cases, approximately 
13% will be bilaterally blinded. In the US, more than half of glaucoma 
suff erers are undiagnosed2. In Latin America, studies show rates of 70% to 
90%, as found in the south of Brazil3. 
In recent years we had many important advances in the diagnosis, 
monitoring and treatment of glaucoma. Th e optical coherence tomography 
(OCT), combined drugs, drainage implants and new insights into the 
pathophysiology of the disease are good example of it. We believe we have 
excellent prospects ahead. In this editorial we will highlight some of them.
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Visual function:
More than doing traditional perimetry, 
researchers are looking for quality of vision and 
its consequence in life of patients. Glaucoma 
patients have a three times higher risk of falls in 
the fi rst year and six times more likely to have 
a motor vehicle collision in the previous fi ve 
years compared with normal subjects as revealed 
by a Canadian study4. As so, physicians should 
warn and orientate their patients. Another 
study5 of University of California San Diego 
(UCSD) reveals similar results 
Imaging:
Now OCTs are in full evolution, both in 
terms of acquisition and evaluation of data6. Th e 
current machines reach 25,000 to 75.000 scans/
second but there are experimental models that 
reach up to 20 million scans/second7. Closer to 
our reality we have three new technologies. Th e 
fi rst one is the swept-source optical coherence 
tomography (SS-OCT) that uses a faster scan 
sweep with a broader band of the spectrum. 
Th is allows 400,000 scans/second and the 
observation of deeper structures such as choroid 
and the lamina cribosa8,9 Th e defects of the 
lamina cribrosa like narrower pores and thicker 
beams are associated with severe glaucoma10. 
Th e evaluation of anterior segment structures 
is also more precise and studies show a good 
ability to identify anterior synechia and angle 
closure, even surpassing the gonioscopy11,12. Th ere 
is already two SS-OCT on the market called 
CASSIA SS-1000 (Tomey, Japan) for anterior 
segment and DRI OCT-1 (Topcon Corporation, 
Itabashi-KU, Japan) for complete eye scans. 
Another technology under development is 
the Adaptive Optics Spectral Domain Optical 
Coherence Tomography (AO-SDOCT), which 
greatly increases the transverse resolution of the 
OCT image by reducing optical aberrations 
caused by the laser beam on the surface of 
the retina. With this, you can now visualize 
photoreceptor, microstructures within the 
RNFL , retinal microvasculature and lamina 
cribosa13,14. For the fi rst time, change in the 
outer layers of the retina in glaucomatous eyes 
were detected, associated with the expected 
changes in the internal layers13. It is an 
impressive breakthrough. In the near future 
this technology will quantify the ganglion cell 
changes consistently in glaucoma evaluation. 
Today we can only have good estimates of them.
A third technology that is under evaluation 
is polarization-sensitive OCT (PS-OCT) that 
utilizes detection of polarized light changes 
in RNFL even before cell death occurs in 
glaucoma15,16,17. It has shown good results in 
early detection of glaucoma compared to current 
OCT technology18. Another promising anterior 
segment utility of PS-OCT is its ability to identify 
fi brosis earlier in the capsular trabeculectomy 
blebs19, which would allow better monitoring of 
the healing postoperatively, increasing survival 
of glaucoma surgeries.
Other technologies are still in development6 at 
early stages. Th e photo-acoustic ophthalmoscopy 
allows identifi cation of retinal blood volume and 
oxygen saturation and the vertical-cavity surface 
emitting laser technology allows visualization 
of the entire thickness of the eye wall. 
Given these advances in imaging technology, 
we have better prospects of understanding 
the pathophysiology of glaucoma and its 
progression. Much is been focused on the 
study of the lamina cribrosa, which is thought 
to be the site of initial damage to the axons of 
the ganglion cells. Spectral OCTs currently in 
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the market do not allow the entire imaging of 
lamina cribrosa and even the new technologies 
described above have signifi cant limitations 
on the visualization of the entire length of 
it. To confi rm the collected data, histological 
comparative studies must be done. Although 
promising and under spotlight, the analysis of 
the cribriform plate is not recommended in 
our routine glaucoma practice at this time 20. 
Intra Ocular Pressure (IOP):
Intra ocular pressure is the only risk factor 
that we can currently modify to decrease 
glaucoma progression. Many eff orts are been 
made for a most accurate and continuous 
method to evaluate IOP in the home settings 
by temporary and permanent methods 21 22.
As a permanent option, there are intraocular 
implants that could be placed during cataract 
surgery behind the iris, like the EyeMate 
(Implandata Ophthalmic Products GmbH, 
Hannover, Germany). Some patients have 
received the implant and are accompanied 
with good results so far. As a temporary option, 
available in the European market, we have the 
Triggerfi sh contact lens (Sensimed AG, Lausanne, 
Switzerland). Its principle is that small changes 
in perilimbic curvature correspond to changes 
in IOP. Th e reproducibility of the data is good 
according to studies23. Th e key issue now is 
to discover the correlation between the data 
collected and the value of IOP in mm Hg, 
which has not yet been possible.
Medications:
 Topical treatment with eye drops is still 
considered and ideal fi rst option to manage 
majority of glaucoma patients. Th e low adherence 
or compliance to treatment is still a crucial 
point in managing glaucoma 24.
Although no new drug class has been 
developed in the last 19 years, the pharmaceutical 
industry is currently working on to develop 
medications that act on the trabecular 
meshwork, increasing the aqueous outfl ow 
and enhancing the action of current drugs. 
Th ere are several drugs with this profi le in 
research as the rho kinase inhibitors25, adenosine 
agonists26, angiotensine type 1 antagonist, 
actin polymerization inhibitor and a serotonin 
receptor antagonist. Th e inhibitors of Rho 
class have a neuroptrotection effect. The 
Rhopressa (Aerie Pharmaceuticals, Durham, 
NC), an inhibitor of Rho kinase, is in Phase 
3 of tests and shows very promising results in 
reducing IOP, either by increasing the aqueous 
outfl ow through the trabecular meshwork or by 
decreased its production27,28. Th ere is emphasis 
on innovations in drug delivery to the point of 
interest or by sustained drug delivery. Contact 
lens29, punctal plugs and fl oating devices in 
the fornix and anterior chamber have been 
tested. Excessive mobility with consequent 
discomfort, irritation and loss of the device are 
the main limitations. Biodegradable implants 
with injectable prostaglandins from Pfi zer and 
pSivida (Watertown, Mass) are already being 
tested in clinical trials. Although presenting 
the risk of a surgical procedure, they have 
longer lasting eff ect (6 months to 1 year) with 
a much lower concentration of drug. Increase 
compliance is crucial goal in the current 
conjecture of glaucoma management.
Surgical Treatment:
 To overcome the l imitations of 
trabeculectomy and drainage implants, 
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currently we have a group of minimally invasive 
glaucoma surgeries (MIGS) that focusses on 
new technologies and techniques. Most of 
these procedures are suitable especially for 
early to moderate glaucoma and still have 
modest results in reducing IOP. In principle, 
these procedures cause less eye infl ammation 
due to lower tissue damage. We can separate 
them as ab interno and as ab externo MIGS 
(Table). Currently FDA approved iStent and 
Trabectome (Neomedix) are widely used to 
manage mild to moderate glaucoma patients 
undergoing cataract surgery. 
Trabecular Micro-Bypass (iStent, Glaukos, 
Laguna Hills, Calif.), which when deployed 
in trabecular meshwork (TM), promotes an 
aqueous direct passage to Schlemm’s canal, 
thereby reducing resistance and IOP. When 
combined with cataract surgery, experienced 
an average reduction of 15-20% in IOP, with 
low rates of complication30,31,32,33 34.
Trabectome removes the TM with high-
frequency electrocautery via ab interno, creating 
a pathway for aqueous directly to Schlemm’s 
canal. There is no thermal damage and 
consequently, a minor harm for surrounding 
tissues. Trabectome spares the conjunctiva and 
there’s no bleb formation. Trabectome is a more 
used device with more publications showing 
good initial results35.
Conclusion: With the advances in 
technology there is paradigm change in 
diagnosing and managing our glaucoma patients 
in the last decade. It is not only important for 
us to stay tuned regarding the changes that are 
happening in our fi eld but is also crucial to 
educate our patients and keep them updated, 
since medical and surgical management of 
glaucoma is going to be more individualized. 
Glaucoma soon will be a curable blindness 
and we believe that we have already started 
the journey to accomplish it.
Filtering surgery Alternative incisional glaucoma surgery 
Tube shunt surgery
(Ahmed, Baerveldt, Molteno) 
Trabeculectomy 
Ex-Press 
Ab externo
Deep sclerectomy /
viscocanaloplasty
Schlemm’s Canal
Canaloplasty 
Eyepass
Suprachoroidal
Gold Shunt
Suprachoroidal microstents
(Cypass)
Trabecular Meshwork microstents
(iStent, Hydrus) 
Trabeculotomy / goniotomy
(Trabectome)
Laser trabeculoplasty 
Subconjuctival microstent
(AqueSys) 
Ab interno
Open-angle glaucomas
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